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Abstract 
Background: Dementia is a slow progressing neurodegenerative disease characterized by loss of 
executive functioning, communication ability, and activities of daily living. With few treatment options 
currently approved for dementia, angiotensin-converting enzyme inhibitors (ACE-I) have been implicated 
as a new potential treatment to slow cognitive decline. ACE-I use in dementia, however, is controversial 
due to conflicting research and new discoveries into the pathophysiology of the brain and ACE. This 
systematic review aims to evaluate the current research on ACE-I use in cognitive decline. 
Methods: Exhaustive search of available medical literature databases including Medline (Ovid/PubMed), 
Google Scholar, Clinical Key, and Web of Science was conducted. Keywords used in the search included: 
Alzheimer’s disease, dementia, ACE inhibitors, angiotensin converting enzyme inhibitors, cognitive 
decline, renin-angiotensin system, and RAS. Alzheimer’s disease (AD) and vascular dementia (VaD) was 
the focus of this review based on the proposed pathophysiology. Studies were included if cognitive 
assessment tools such as the mini mental status exam, mini-cog or Qmci, were assessed at baseline and 
an end-point with a minimum of 6 months. Articles were assessed for quality using the GRADE criteria. 
Results: Five studies met inclusion criteria and were evaluated. Three of the studies found were 
observational, one study was a randomized controlled trial, and one was a cohort study. With the 
exception of one very low quality study, the results were consistent that ACE-I may provide slowing of the 
progression of cognitive decline in dementia patients. 
Conclusion: Current research on dementia progression and ACE inhibitors, as measured by cognitive 
assessment tools, have been shown to slow cognitive decline in elderly patients. Further research, 
preferably multiple, large randomized controlled human trials are necessary to determine the risk versus 
benefit of ACE inhibitor use. 
Keywords: Alzheimer’s disease, dementia, ACE inhibitors, angiotensin converting enzyme inhibitors, 
cognitive decline, renin-angiotensin system, RAS. 
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Abstract 
Background: Dementia is a slow progressing neurodegenerative 
disease characterized by loss of executive functioning, communication 
ability, and activities of daily living. With few treatment options 
currently approved for dementia, angiotensin-converting enzyme 
inhibitors (ACE-I) have been implicated as a new potential treatment 
to slow cognitive decline. ACE-I use in dementia, however, is 
controversial due to conflicting research and new discoveries into the 
pathophysiology of the brain and ACE. This systematic review aims to 
evaluate the current research on ACE-I use in cognitive decline.   
Methods:  Exhaustive search of available medical literature databases 
including Medline (Ovid/PubMed), Google Scholar, Clinical Key, and 
Web of Science was conducted. Keywords used in the search included: 
Alzheimer’s disease, dementia, ACE inhibitors, angiotensin converting 
enzyme inhibitors, cognitive decline, renin-angiotensin system, and 
RAS. Alzheimer’s disease (AD) and vascular dementia (VaD) was the 
focus of this review based on the proposed pathophysiology. Studies 
were included if cognitive assessment tools such as the mini mental 
status exam, mini-cog or Qmci, were assessed at baseline and an end-
point with a minimum of 6 months. Articles were assessed for quality 
using the GRADE criteria.  
Results: Five studies met inclusion criteria and were evaluated. Three 
of the studies found were observational, one study was a randomized 
controlled trial, and one was a cohort study. With the exception of one 
very low quality study, the results were consistent that ACE-I may 
provide slowing of the progression of cognitive decline in dementia 
patients.  
Conclusion:  Current research on dementia progression and ACE 
inhibitors, as measured by cognitive assessment tools, have been 
shown to slow cognitive decline in elderly patients. Further research, 
preferably multiple, large randomized controlled human trials are 
necessary to determine the risk versus benefit of ACE inhibitor use. 
Keywords: Alzheimer’s disease, dementia, ACE inhibitors, angiotensin 
converting enzyme inhibitors, cognitive decline, renin-angiotensin 
system, RAS. 
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Can Angiotensin-Converting Enzyme Inhibitors 
Slow the Progression of Cognitive Decline In 
Elderly Patients With Dementia?  
 
BACKGROUND 
One in nine patients in the United States over the age of sixty-
five have been diagnosed with dementia, a disease defined by an 
insidious, progressive, and significant decline in higher cognitive 
function.1 Dementia types include Alzheimer’s disease (AD), Lewy body 
dementia and Parkinson disease with dementia, frontotemporal 
dementia, and vascular (multi-infarct) dementia (VaD).1 Despite these 
different sub-diagnoses, patients share difficulty with both executive 
functioning and activities of daily living (ADL). Deficits can include 
changes in learning, memory, language, attention, perceptual-motor 
function, and social cognition. In addition, these symptoms are 
associated with a high frequency of psychiatric changes such as 
depression.11 These debilitating changes place a large emotional, 
physical, and financial burden on caregivers.  
Unfortunately, treatment options are lacking and have been 
limited to N-methyl-D-aspartate (NMDA) receptor antagonists, 
cholinesterase inhibitors, as well as symptomatic care.1 These 
medications are only marginally successful and a cure for dementia 
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has yet to be found. Current avenues of research have been focused 
on risk reduction, namely with genetic and cardiovascular risk factors. 
Angiotensin converting enzyme inhibitors (ACE-I) have been 
implicated as a potential new avenue of treatment, although their use 
in cognitive improvement is not without some controversy.   
 The renin-angiotensin system (RAS) has been thoroughly studied 
in the brain and is thought to be independent to that of the peripheral 
RAS system.2 Traditionally, the RAS system includes renin acting on 
angiotensinogen to produce angiotensin I, which is then later cleaved 
by ACE to angiotensin II. Angiotensin II is associated with 
vasoconstriction and an increase in blood pressure (BP); one of the 
major risk factors for VaD and AD development. Angiotensin II is also 
associated with inhibition of acetylcholine release in the brain, an 
important avenue of the current drug therapy. It is hypothesized that 
inhibition of ACE may contribute to increases in acetylcholine and 
therefore improve cognitive function.7 
It has now been observed that angiotensinogen cleaves into 
many different neuropeptides in the brain. These may mediate neuro-
cognitive processes such as memory, processing sensory information, 
emotions, and learning.2 Moreover, high levels of angiotensin 
receptors are found in areas of the brain associated with cognitive 
function and memory such as the cortex, hippocampus, and amygdala. 
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The involvement of the role of ACE in relation to these various 
angiotensins and their receptors is still being investigated. The 
pathophysiology and role of ACE in the brain is further complicated by 
another proposed mechanism.  
 Alzheimer’s disease, in particular, is marked by amyloid-beta 
(A) protein aggregation and plaque formation. In animal models, ACE 
has been shown to degrade A protein aggregation.8 In addition, a 
study in 20146 examined the relationship between ACE inhibition, A 
levels, and ACE in the CSF, further bolstering the current animal model 
research stating ACE has a helpful role in degradation of protein 
aggregates. In other words, inhibiting ACE via medication may 
increase plaque formation. The mechanism for which this occurs, is 
still being investigated. This finding, however, is inconsistent in the 
literature. Other animal model trials illustrated that despite injections 
of A, cognitive outcomes were better with use of certain brain-
penetrating ACE-Is.7 
 The extent of RAS involvement in the development of dementia 
is still unknown. The effect of ACE in relation to the pathophysiology of 
VaD and AD are also unresolved.  This paper aims to review the 
current literature regarding ACE inhibitors and the progression of 
cognitive decline.   
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METHODS 
An exhaustive systematic search of online databases including 
Medline (Ovid/PubMed), Google Scholar, Clinical Key, and Web of 
Science was conducted. Keywords used in the search included: 
Alzheimer’s disease, dementia, ACE inhibitors, angiotensin converting 
enzyme inhibitors, cognitive decline, renin-angiotensin system, and 
RAS. In addition, the reference sections of relevant articles were also 
screened for pertinent studies.  
 Studies were included if patients involved were diagnosed with 
dementia according to National Institute of Neurological Clinical 
Disorders and Stroke (NINCDS) standards, National Institute of 
Neurological and Communicative Diseases and Stroke-Alzheimer’s 
Disease and Related Disorders Association (NINCDS-ADRDA), or the 
current Diagnostic and Statistical Manual (DSM-V). Based on the 
proposed mechanism of action of ACE inhibitors, only Alzheimer’s 
dementia and/or vascular dementia types were included. All types of 
ACE inhibitors, both centrally acting and non-centrally acting were also 
included. Use of recognized cognitive diagnostic measures such as 
MMSE, MOCA, and Qmci, both before and after ACE inhibition, were 
necessary to track the progression of cognitive decline. A minimum 
total length of study for at least six months between baseline and 
subsequent cognitive testing was a requirement for inclusion.  
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 The articles that were excluded did not take into account co-
morbid factors such as years of education, history or current 
hypertension, cardiovascular disease, or depression that may have 
worsened dementia progression and outcomes. Studies that were 
based on specific diagnostic biomarkers or other objective measurable 
effects aside from cognitive assessment tools were also excluded. Non-
English language articles or studies based on animal trials were 
excluded as well.  
 The quality of these articles was assessed using the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) 
Working Group guidelines.  
 
RESULTS 
The review of the literature yielded a total of five studies that 
matched the aforementioned inclusion criteria. Due to the nature of 
dementia and the cognitive assessment tools used, most studies are 
observational with the exception of one randomized control trial 
completed in 20043 and one cohort study.11 After searching the 
reference sections of each article, no further studies were found to fit 
the criteria outlined in this review.   
CAOIMH et al (2013) 
 This observational study is a secondary analysis of a previous 
randomized controlled trial (RCT) from the Doxycycline and Rifampin 
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for Alzheimer’s Disease trial (DARAD). Participants were aged 50 years 
or more and were diagnosed with mild to moderate dementia based on 
the National Institute of Neurological Disorders and Stroke (NINCDS) 
criteria. Patients included in the study were from 14 geriatric 
outpatient clinics in Canada.  
The study aimed to compare the rate of functional decline in 
patients using centrally acting angiotensin-converting enzyme 
inhibitors (CACE-I) compared to no CACE-I use. The CACE-I group was 
further divided into two groups, those using the specific CACE-I, 
Perindopril, and those who were using other CACE-Is. Perindopril has 
been shown to prevent cognitive impairment in mouse models, and 
therefore was analyzed more carefully in this study.9 Out of a total 
sample of 406 participants, 41 were excluded. The excluded patients 
were reported as either lost to follow up, withdrawal from the trial, 
adverse events (unspecified), or other reasons such as moving or 
caregiver death. The CACE-I group was smaller (n=91) than the no 
CACE-I (n=274). The group taking CACE-I Perindopril was also smaller 
(n=21) compared to other CACE-I use (n=70).  
Secondary outcomes for the DARAD trial included multiple 
cognitive assessment tools including the Qmci as well as other 
measures of ADL and cognition. Baseline and end-point scores were 
collected at an interval of 12 months. Background factors such as age, 
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gender, years of education, blood pressure, cholinesterase inhibitor 
use and memantine use were taken into account and adjusted for in 
the analysis of data (multivariate regression analysis). The Qmci 
median interquartile range at baseline (4) versus at follow up 12 
months later (5) showed a 20% slower rate of decline for the CACE-I 
group. In addition, perindopril was found to have slower rates of 
decline with Qmci. However, these finding were not statistically 
significant. The statistical significance in this study lies with the 
assessment of ADLs with the Lawton-Brody ADL scale, which showed a 
25% reduction in the rate of decline over 12 months (p=0.034, 
adjusted for baseline factors).  
Researchers in this study focused on the rate of functional 
decline, as compared to cognitive decline, however the results 
continue to support the use of CACE-I in the reduction of rate of 
disease progression in dementia.  
GAO et al (2013) 
 Cognitive decline in dementia patients was observed in this 
study by comparing three groups; CACE-I, no CACE-I, and new CACE-I 
(patients who started CACE-Is during the first 6 months of treatment). 
Participants were sampled from two university hospital memory clinics 
in Canada via the Geriatric Assessment Tool database. All patients 
were diagnosed with dementia via the NINCDS guidelines. This study 
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included only AD, vascular, and mixed dementias (AD/vascular 
combinations). Participants were excluded if they had other types of 
dementia, normal or only mild cognitive impairment, or associated/co-
morbid depression. Patients were also screened for depression with the 
Geriatric Depression Scale and were excluded if depression was found. 
This was done because it is shown that depression can negatively 
affect the results of cognitive testing. Characteristics such as age, 
gender, education, blood pressure, cholinesterase inhibitor use, and 
memantine use were also compared between groups. The participants 
ages were reported as 77.2 + 6.4, with 50.3% of them being male, 
and with an average of 11.2 years of education. These demographics 
were similar across all groups. These characteristics were adjusted for 
in all analyses.  
Baseline and end-point SMMSE and Qmci were used to measure 
cognitive decline. End-point testing was performed at 6 months by 
trained nurses who were blind to the diagnosis. Gao et al explain that 
a 6-month interval was chosen based on the fact that the US Food and 
Drug Administration requests this amount of time to pass before 
assessing the benefit from new medications for cognitive decline. 
Number of participants with SMMSE and Qmci scores differed 
significantly between groups; CACE-I (SMMSE 83, Qmci 41), No CACE-
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I (SMMSE 270, Qmci 114), New CACE-I (SMMSE 30, No Qmci 
participants).  
Nevertheless, the study found that there were statistically 
significant changes for Qmci scores within 6 months for CACE-I 
(p=0.049). In addition, the New CACE-I group showed a median 
improvement in SMMSE scores compared to the other groups, rather 
than a cognitive decline. Interestingly this study showed that the use 
of CACE-I may be most beneficial within the first 6 months, as 
compared to those on maintenance CACE-I. Gao et al attribute this to 
possible effects of medication compliance, improved BP control, or 
increased cerebrovascular perfusion.   
HAJJAR et al (2008) 
 Hajjar et al is an observational, prospective, and longitudinal 
study that assessed both cognitive and functional decline in AD. 
Cognitive assessments included the MMSE, clock draw test, and 
working memory (digit ordering). For the purposes of comparison, 
MMSE will be the focus of the analysis of this paper. Participants with 
mild to moderate AD were recruited between July 2004 through June 
2005 through a geriatric primary care practice and memory disorders 
clinic. The study included participants who were diagnosed with 
possible or probable AD according to the National Institute of 
Neurological and Communicative Diseases and Stroke-Alzheimer’s 
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Disease and Related Disorders Association (NINCDS-ADRDA). 
Dementia types other than AD were excluded.  
The participants also had to be older than 55 years of age, have 
a reliable caregiver, and perform cognitive and functional assessments 
at the study center. Exclusions were based on previous cardiovascular 
and neurological history (atrial fibrillation, myocardial infarct, stroke, 
delirium, seizures). Patients with depression were receiving 
antidepressants were allowed into the study if they had been on a 
stable dose for 6 months prior to the study start date. Recruitment for 
the study was done at geriatric primary care facilities, memory 
disorder clinics, as well as announcements at retirement homes, senior 
centers, and assisted living communities. A total of 62 participants 
were enrolled, however 10 were lost to follow up. Demographic 
information, family history, medication history, and history of alcohol 
or tobacco use was obtained. No change in use of ACE-I or 
acetylcholinesterase inhibitors was found during the study period.  
Participants were categorized into ACE-I use and no ACE-I use. 
Cognitive and functional assessments were collected at baseline, 3 
months, and 6 months. For the purposes of this review, measurements 
at 6 months were compared to those at baseline. At baseline no 
differences were found between groups at baseline in terms of age, 
gender, race, education, or cognitive or functional assessments. The 
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results of the study showed that for cognitive assessments (MMSE, 
clock draw test, and the digit ordering test) there was no statistical 
significance found, although there was a trend in slower decline. This 
study did demonstrate an improvement in ADLs in the ACE-I group 
versus the no ACE-I use group (P=0.005). Assessment of caregiver 
stress was also found to be significant (P=0.03 un-adjusted, P=0.04 
adjusted). These results reveal that ACE-I have significant effects on 
functional decline.  
OHRUI et al (2004) 
 Ohrui et al was the only randomized control trial found in the 
search of the literature. The study’s goals were to determine the effect 
of ACE-I, specifically brain-penetrating inhibitors, on AD patients 
exposed to medications over a one-year period. Participants were 
chosen based on the NINCDS-ADRDA criteria from three long term 
care facilities in Sendai, Japan. These participants were 65 years of 
age and older with baseline MMSE scores putting them in the 
moderate dementia category (13 to 23). Patients were screened and 
eliminated from the study if they had a history of cardiovascular 
disease, renal failure, psychiatric disease, drug use or dependency. 
Although patients with co-morbid conditions such as cardiac 
arrhythmias, hypercholesterolemia, or osteoporosis were not excluded 
from the research criteria, they were represented in equal proportion 
throughout the three research groups.  
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In addition, the patients all underwent brain MRI studies to 
exclude patients with possible vascular or other types of dementia in 
order to focus as closely as possible to the effect of these medications 
on Alzheimer’s disease. Other medications such as anticholinergics, 
anticonvulsants, antipsychotics or antidepressants were removed from 
the study. However, if the participant was on a stable cholinesterase 
inhibitor dose, statin, or low-dose aspirin, these were allowed. The 
number of participants on each of these medications was similar in all 
groups as well.  
Patients (n=182) were randomly assigned into three groups of 
medication treatment; Group A: brain penetrating ACE-I (n=51), 
Group B: non-brain penetrating ACE-I (n=53), or Group C: calcium 
channel blocker (n=58). MMSE scores were used to measure cognitive 
status at baseline and at one-year. During the course of treatment, 
only one participant was lost to follow up due to hypotension.  
Results indicated that there was a slower cognitive decline for 
patients taking brain penetrating ACE-I (group A) compared to both 
groups B and C (p=0.0023 and p<0.001, respectively). This indicates 
that brain penetrating ACE-I could slow the rate of cognitive decline in 
AD. Ohrui et al10 state that the rate of decline for groups B and C were 
more severe than in previous studies, and therefore those that had 
significant decline (MMSE score decline of 6 points or greater) were re-
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evaluated and were shown to have more impairment with ADL. Once 
these outliers were removed and the data was re-analyzed, groups B 
and C rates of MMSE decline were comparable to prior studies. 
Therefore, the researchers propose that the most benefit may be 
found with those patients started on a brain-penetrating ACE-I with 
mild ADLs to prevent rapid decline in MMSE scores.   
SOTO et al (2013) 
 This cohort study had the longest baseline to endpoint time of 
four years, with biannual assessment of the MMSE by a memory 
expert physician. It also had the largest starting sample size of any 
study reviewed (n=686). Participants met dementia criteria according 
to the DSM and NINCDS-ADRDA standards. Only mild to moderate 
dementia patients were included, as defined by MMSE scores. 
Participants were acquired in 16 specialized memory clinics in France 
from April 2000 to October 2002. Caregiver support was also a 
requirement of this study. Brain CT scans were obtained at baseline to 
rule out any vascular lesions. 
 The participants were then grouped into four categories based 
on their use of hypertensive medications: continuous/intermittent 
other drug users, continuous ACE inhibitors users, intermittent ACE 
inhibitors users, and never drug users. Trained nurses obtained drug 
use information at each of the biannual visits. Continuous users were 
defined as patients who reported using the same medication at both 
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visits. Intermittent users were defined as patients that discontinued or 
started an ACE-I during the study. Participants who were taking 
angiotensin II receptor blockers (ARBs) were excluded to assess the 
sole effect of ACE-I use.  
 Confounding factors such as sociodemographic characteristics, 
ADLs, behavioral and psychiatric conditions, and cardiovascular 
disease and risk factors were taken into account and adjusted for in 
the analysis of the data. Both unadjusted and adjusted data were 
presented without loss of significance in data. There were no 
significant changes in baseline MMSE scores between groups.  
 Unfortunately, there was a substantial loss of patients during 
follow-up, some of which dropped out of the study, died, were 
institutionalized, had caregiver health problems, or were unable to be 
contacted. At the 6-month assessment there were 513 completers. By 
the end of the 48-month assessment, there were a total of 179 
completers. In total, for the continuous users of ACE-I group 70.5% of 
patients dropped out, in the intermittent users of ACE-I 59.6% 
dropped out, 66.1% of continuous or intermittent users of other 
antihypertensive drugs dropped out, and lastly, 68.1% of never users 
dropped out. 11 
 Results showed a significant difference in MMSE scores between 
the groups as the study progressed. In comparing the continuous ACE-
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I group to the never used antihypertensive drugs group, the MMSE for 
continuous ACE-I users showed significantly less decline (MMSE 
decline difference of -4.9 + 1.8, p=0.01). However, when comparing 
the continuous versus intermittent ACE-I users, no significant 
difference was found (MMSE decline difference -3.1 + 1.8, p=0.06). 
Continuous ACE-I users were also compared to the users of other 
antihypertensive drugs group. This comparison also revealed no 
significant difference in decline (MMSE decline difference -2.6 + 1.9, 
p=0.20). The researchers state that in restricted analysis, however, 
participants that used ACE-I continuously or intermittently did show 
slower rates of cognitive decline compared to the two control groups. 
The significance in the data began in the second, third and fourth 
years (p=0.05, p=0.04, p=0.03 respectively). Due to the loss of follow 
up, Soto et al also calculated differences between the groups with 
slope analysis to represent the trend of the data. MMSE decline in both 
unadjusted (p<0.04) and adjusted (p<0.02) were significant.  
 The data presented in this study suggests that both continuous 
and intermittent use of ACE-I help to slow the progression of cognitive 
decline in MMSE scores compared to other hypertensive users or those 
that take no hypertensive medications. A secondary analysis was then 
done to determine any significance with users of ARBs, of which no 
significance was found. The evidence presented by Soto et al also 
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suggest that ACE-I may have a separate mechanism by which they 
have cognitive benefits due to the superior change in MMSE scores 
compared to participants taking other antihypertensive medications.  
DISCUSSION 
Current dementia treatment is limited, giving both healthcare 
providers and family members few options. No current treatment 
exists to halt the progression of the disease, however the ability to 
preserve or slow cognitive decline is the primary goal. Angiotensin 
converting enzyme inhibitors have shown evidence to slow the rate of 
cognitive decline in elderly patients with dementia.3,5,10 As a secondary 
adjunct to this analysis, ACE inhibitors also have been demonstrated 
to improve functional decline in relation to activities of daily living and 
caregiver burden.3,5,9 While ADLs and caregiver burden are difficult to 
objectify, the value of allowing elderly patients greater function is 
priceless. This research implies the potential benefit of ACE inhibitors 
for dementia treatment.  
Three studies3,9,10 in particular investigated the effect of centrally 
acting or brain penetrating ACE-I. Medications that are considered 
brain penetrating include enalapril, perindopril, captopril or Lisinopril. 
However, these medications may have different levels of brain 
penetration, which are unknown. In this regard, all ACE-I are not 
created equal and more research needs to be conducted on the 
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differences of these prescriptions.7 If certain brain penetrating ACE-I 
are found to be more neuro-protective than others, this could change 
potential recommendations for which type of ACE-I could be effective 
in the demented patient.   
Despite the cognitive benefits outlined in this review, we still do 
not understand the mechanism for which ACE inhibition acts on the 
brain of the demented patient. However, the research presented has 
adjusted in its analyses for measurements of blood pressure, 
suggesting that the benefits of ACE-I are independent of hypertension. 
In addition, most of the controversy surrounding ACE-I use for 
dementia is dependent on animal research. Animal models may not 
completely mimic the multifactorial components involved in cognition 
in the adult human and therefore this review aimed to focus solely on 
human outcomes.  
Research on ACE-Is and dementia as a whole are not without 
limitations. Areas for further research are vast. For instance, we do not 
yet know if these potential benefits are dose dependent. Furthermore, 
it is important to recognize that medication compliance can be un-
reliable at times with the geriatric population. Polypharmacy is also 
common. While many of these studies tried to adjust for the use of 
other medications, specifically those that effect cognition such as 
memantine or cholinesterase use, it is sufficiently challenging to find a 
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patient population where the effects of other medications can be 
ignored. Moreover, four out of the five studies reviewed3,5,9,11 cannot 
account for the length of treatment with ACE-I prior to the start of 
their study date.  
 Other limitations of the articles reviewed5 may be in the study 
design. Changes in symptoms of dementia are often insidious and slow 
progressing. There is question as to whether a six-month interval from 
baseline to end-point is too short. In addition, practice effects in 
neuropsychological testing are confounders that may result from task 
familiarity in directions and context of the test. Familiarity with specific 
items on the test such as words on a list or other items of recall may 
also occur.4 Study design with as many participants as possible is also 
needed. Gao et al3 and Hajjar et al5 were downgraded by GRADE 
criteria due to small sample size.  
 In total, many of the studies presented in this review are 
observational.3,5,9 According to the GRADE assessment, these studies 
are rated as low in quality. However, these studies collectively do show 
a positive effect for the potential use of ACE-I in dementia treatment. 
For the Gao et al (2013) study3, it is also important to recognize 
inherent bias in that treatment options were given based on provider 
clinical judgement, and therefore these clinical recommendations may 
change from clinician to clinician. Further large-volume randomized 
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controlled trials will be needed to continue to investigate ACE inhibition 
on cognition in the demented elderly. This research could also be 
further expanded to include different dementia subgroups such as 
younger onset dementia or ACE-I could be used to study early 
intervention treatments.  
 
CONCLUSION 
No recommendations currently exist for the use of ACE inhibitors for 
risk reduction of dementia in the clinical setting, however research is 
promising for further avenues of treatment. Investigations into the 
pathophysiology involved are needed. Further research, preferably 
multiple, large randomized controlled human trials are also necessary 
to determine the risk versus benefit of ACE inhibitor use. Hopefully 
with further research the controversy of whether or not ACE inhibitors 
are helpful or harmful to dementia patients will be resolved. The 
systematic review of this issue shows evidence for the potential future 
use of ACE-I as another avenue of treatment for dementia.   
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Table 1: Quality Assessment of Reviewed Articles 
Study Design 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Gao et al Observational  Not 
Serious 
Not serious  Not serious Seriousa Unlikely None Low 
Hajjar et al Observational  Not 
Serious 
Not serious  Not serious Seriousb Unlikely  None Very Low 
O-Caoimh et al Observational, 
secondary 
analysis 
Not 
Serious 
Not serious Not serious Not serious Unlikely  None Low 
Ohrui et al RCT Seriousc Not serious Not serious  Not serious Unlikely None Moderate 
Soto et al Cohort  Not 
serious 
Not serious  Not serious Not serious Unlikely  None Low 
aSmall sample size between groups in SMMSE and Qmci  
bSmall sample size  
cStudy does not report any evidence of allocation concealment or blinding  
 
 
 
 
  
